In line with this, an early-phase clinical trial initiated by the Massey Cancer Center, which is investigating the combination of sorafenib and Vorinostat, has also provided preliminary evidence of the potential of HDAC inhibitors in the treatment of HCC (Gordon et al., 2019). This evidence concerns the gene HDAC9 and hepatocellular carcinoma.